Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock
BMO Capital Market upgraded Fate Therapeutics Inc (NASDAQ:FATE) to Outperform from Market Perform. The analyst believes Fate’s iPSC platform is uniquely positioned…